R. Mahabaleshwarkar
University of Mississippi
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by R. Mahabaleshwarkar.
Population Health Management | 2012
R. Khanna; Pf Pace; R. Mahabaleshwarkar; Ram Sankar Basak; M. Datar; Benjamin F. Banahan
Limited information is currently available about medication adherence for common chronic conditions among the Medicaid population. The primary objective of this study was to assess medication adherence among Medicaid recipients with depression, diabetes, epilepsy, hypercholesterolemia, and hypertension. Factors influencing adherence were determined. The authors also assessed whether adherence influences the utilization of acute care services. The target population included nonelderly adult recipients (ages 21-64 years) who were continuously enrolled in the Mississippi (MS) Medicaid fee-for-service program from January 1, 2006 to December 31, 2007. Recipients were identified who had a medical services claim with a diagnosis of depression, diabetes, epilepsy, hypercholesterolemia, or hypertension in calendar year 2006. Within each chronic disease sample, medication adherence was determined using calendar year 2007 data for recipients who met inclusion and exclusion criteria. Recipients with adherence ≥80% were classified as adherent. Logistic regression analyses were used to determine the factors that predict medication adherence and the effect of adherence on concurrent all-cause acute care service (ie, hospitalization, emergency room visit) utilization. Approximately 24% of recipients with depression, 35.9% with diabetes, 53.6% with epilepsy, 32% with hypercholesterolemia, and 42.2% with hypertension were adherent. Within each chronic disease sample, males and whites had higher adherence than females and blacks. After controlling for demographic and disease-related covariates, recipients who were adherent had lower concurrent acute care service utilization than nonadherent recipients. Given the inverse relationship between adherence and acute care service utilization, policy makers should consider implementing educational interventions aimed at improving adherence in this underprivileged population.
Population Health Management | 2013
R. Mahabaleshwarkar; Rahul Khanna; Donna West-Strum; Y Yang
Conflicting information currently exists about the role played by health-related quality of life (HRQOL) in influencing colorectal cancer screening. The current study aimed to determine the relationship between HRQOL and colorectal cancer screening, using nationally representative public data from the Behavioral Risk Factor Surveillance System (BRFSS). The 2010 BRFSS data were used for this study. Individuals younger than age 50 years were excluded from the study. Missing data were imputed using the multiple imputation technique. Multiple multivariate logistic regression models were fitted to the data to determine the association between different components of HRQOL (physical HRQOL, mental HRQOL, activity limitation caused by poor mental or physical HRQOL, and general health status) and receipt of colorectal cancer screening tests (fecal occult blood testing [FOBT] in the past year, sigmoidoscopy in the past 5 years, and colonoscopy in the past 10 years). The study sample comprised 301,488 individuals. Approximately 12% of the respondents had received FOBT in the past year, 62.6% had received sigmoidoscopy in the past 5 years, or colonoscopy in the past 10 years, and 65.4% had received either of the screening tests within appropriate time frames. After controlling for demographic and health-related covariates, an inverse relationship was observed between HRQOL and colorectal cancer screening with the exception of mental HRQOL and FOBT. The relationship between mental HRQOL and FOBT was found to be nonsignificant. Policy makers should consider including HRQOL as an important parameter when designing interventions aimed at improving colorectal cancer screening rates.
Current Medical Research and Opinion | 2013
R. Mahabaleshwarkar; Y Yang; M. Datar; John P. Bentley; M. Strum; Benjamin F. Banahan; K.D. Null
Abstract Objective: To examine the effect of concomitant use of clopidogrel and PPIs in a national sample of elderly Medicare beneficiaries (age ≥65 years). Methods: A nested case–control design was employed. A cohort of Medicare beneficiaries who initiated clopidogrel and did not have any gap of ≥30 days between clopidogrel fills between July 1, 2006 and December 31, 2008 was identified from a 5% national sample of Medicare claims data. Within this cohort, cases (beneficiaries who experienced any major cardiovascular event [MCE] [acute myocardial infarction, stroke, coronary artery bypass graft, or percutaneous coronary intervention] or all-cause mortality) and controls (beneficiaries who did not experience any MCE or all-cause mortality) were identified from inpatient and outpatient claims. Cases and controls were matched on age and the time to first clopidogrel fill. Conditional logistic regression was performed on the matched sample to evaluate the association between concomitant use of clopidogrel and PPIs and adverse health outcomes (MCEs and all-cause mortality). Results: A total of 43,159 clopidogrel users were identified. Among them, 15,415 (35.7%) received clopidogrel and a PPI concomitantly at any time during the study period, 3502 (8.1%) experienced a MCE, 7306 (17.1%) died, and a total of 9908 (22.8%) experienced the primary composite outcome (any MCE or all-cause mortality) during follow-up. The odds ratio (OR) for the primary composite outcome was 1.26 (95% confidence interval [CI]: 1.18–1.35). Secondary analyses indicated that elderly patients using clopidogrel and a PPI concomitantly were more likely to experience all-cause mortality (OR: 1.40; 95% CI: 1.29–1.53) as compared to those receiving clopidogrel only, but not MCEs (OR: 1.06; 95% CI: 0.95–1.18). Conclusions: Concomitant use of clopidogrel and PPIs was associated with a slightly increased risk of all-cause mortality but not MCEs.
Research in Autism Spectrum Disorders | 2014
R. Khanna; Krutika Jariwala-Parikh; Donna West-Strum; R. Mahabaleshwarkar
Research in Social & Administrative Pharmacy | 2015
R. Khanna; R. Mahabaleshwarkar; Erin R. Holmes; K. Jariwala
Value in Health | 2014
R. Mahabaleshwarkar; R. Khanna; Benjamin F. Banahan; Donna West-Strum; Y Yang; J. Hallam
Value in Health | 2014
R. Shah; R. Mahabaleshwarkar; K.D. Null; J.P. Clark
Value in Health | 2014
R. Mahabaleshwarkar; R. Khanna; Benjamin F. Banahan; Donna West-Strum; Y Yang; J. Hallam
Value in Health | 2014
R. Khanna; K. Jariwala; Donna West-Strum; R. Mahabaleshwarkar
Value in Health | 2014
R. Khanna; K. Jariwala; Donna West-Strum; R. Mahabaleshwarkar